PURPOSE: The purpose of this study was to evaluate the risk factors associated with the treatment failure and 30-day mortality in hematology and bone marrow transplant patients treated with daptomycin or linezolid for vancomycin-resistant enterococci (VRE) bacteremia. The safety and tolerability of therapy was also assessed. METHODS: This single-center, retrospective study included adult patients admitted to the hematology or bone marrow transplant service with documented vancomycin-resistant Enterococcus faecium or Enterococcus faecalis bacteremia and received at least 48 h of either linezolid or daptomycin as primary treatment. Clinical and microbiologic outcomes were assessed at day 7, 14, and 30 of hospital stay. RESULTS: A total of 72 patients were included in the analysis. Forty-three patients received daptomycin as primary treatment and 29 received linezolid as primary treatment. Overall success rate at day 7 was 81.9%, day 14 success rate was 79.2%, and day 30 success rate was 76.4% for all patients. Forty-one patients (57.0%) had high-grade bacteremia defined as greater than one positive blood culture for VRE. The mortality rate was significantly higher if high-grade bacteremia was present (34.1% vs. 7.0%; p = 0.009). CONCLUSIONS: This study suggests that linezolid and daptomycin are both reasonable options for treating VRE bacteremia in hematology and bone marrow transplant patients; however, patients with high-grade VRE bacteremia may be at increased risk for treatment failure.
PURPOSE: The purpose of this study was to evaluate the risk factors associated with the treatment failure and 30-day mortality in hematology and bone marrow transplant patients treated with daptomycin or linezolid for vancomycin-resistant enterococci (VRE) bacteremia. The safety and tolerability of therapy was also assessed. METHODS: This single-center, retrospective study included adult patients admitted to the hematology or bone marrow transplant service with documented vancomycin-resistant Enterococcus faecium or Enterococcus faecalisbacteremia and received at least 48 h of either linezolid or daptomycin as primary treatment. Clinical and microbiologic outcomes were assessed at day 7, 14, and 30 of hospital stay. RESULTS: A total of 72 patients were included in the analysis. Forty-three patients received daptomycin as primary treatment and 29 received linezolid as primary treatment. Overall success rate at day 7 was 81.9%, day 14 success rate was 79.2%, and day 30 success rate was 76.4% for all patients. Forty-one patients (57.0%) had high-grade bacteremia defined as greater than one positive blood culture for VRE. The mortality rate was significantly higher if high-grade bacteremia was present (34.1% vs. 7.0%; p = 0.009). CONCLUSIONS: This study suggests that linezolid and daptomycin are both reasonable options for treating VRE bacteremia in hematology and bone marrow transplant patients; however, patients with high-grade VRE bacteremia may be at increased risk for treatment failure.
Authors: Leonard A Mermel; Michael Allon; Emilio Bouza; Donald E Craven; Patricia Flynn; Naomi P O'Grady; Issam I Raad; Bart J A Rijnders; Robert J Sherertz; David K Warren Journal: Clin Infect Dis Date: 2009-07-01 Impact factor: 9.079
Authors: Debra D Poutsiaka; Serena Skiffington; Kenneth B Miller; Susan Hadley; David R Snydman Journal: J Infect Date: 2006-12-26 Impact factor: 6.072
Authors: P F Smith; M C Birmingham; G A Noskin; A K Meagher; A Forrest; C R Rayner; J J Schentag Journal: Ann Oncol Date: 2003-05 Impact factor: 32.976
Authors: S M Bhavnani; J A Drake; A Forrest; J A Deinhart; R N Jones; D J Biedenbach; C H Ballow Journal: Diagn Microbiol Infect Dis Date: 2000-03 Impact factor: 2.803
Authors: D L Shinabarger; K R Marotti; R W Murray; A H Lin; E P Melchior; S M Swaney; D S Dunyak; W F Demyan; J M Buysse Journal: Antimicrob Agents Chemother Date: 1997-10 Impact factor: 5.191
Authors: Bernard C Camins; Monica M Farley; John J Jernigan; Susan M Ray; James P Steinberg; Henry M Blumberg Journal: Infect Control Hosp Epidemiol Date: 2007-06-29 Impact factor: 3.254
Authors: M Tavadze; L Rybicki; S Mossad; R Avery; M Yurch; B Pohlman; H Duong; R Dean; B Hill; S Andresen; R Hanna; N Majhail; E Copelan; B Bolwell; M Kalaycio; R Sobecks Journal: Bone Marrow Transplant Date: 2014-08-11 Impact factor: 5.483
Authors: Kenneth V I Rolston; Dina Besece; Kenneth C Lamp; Min Yoon; Scott A McConnell; Pamela White Journal: Support Care Cancer Date: 2013-08-24 Impact factor: 3.603